Everest Medicines (HKSE:01952) Other Current Payables: HK$326 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01952 Everest Medicines Ltd HKSE:01952
42 GF Score
Price HK$31.10
GF Value HK$210.70
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Everest Medicines Other Current Payables?

Everest Medicines HKSE:01952 -1.08% 42 Other Current Payables is HK$326 Mil as of Jun. 2026. GuruFocus rates HKSE:01952 with a GF Score™ of 42/100 and a GF Value™ of HK$210.70 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Everest Medicines's Other Current Payables for the quarter that ended in Jun. 2026 was HK$326 Mil.

Everest Medicines's quarterly Other Current Payables increased from Jun. 2025 (HK$177 Mil) to Dec. 2025 (HK$418 Mil) but then declined from Dec. 2025 (HK$418 Mil) to Jun. 2026 (HK$326 Mil).

Everest Medicines's annual Other Current Payables increased from Dec. 2023 (HK$214 Mil) to Dec. 2024 (HK$273 Mil) and increased from Dec. 2024 (HK$273 Mil) to Dec. 2025 (HK$418 Mil).

Everest Medicines Other Current Payables Related Terms

Everest Medicines Other Current Payables Historical Data

* Premium members only.

The historical data trend for Everest Medicines's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Everest Medicines Other Current Payables Chart

Everest Medicines Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial 161.72 0.00 214.31 272.91 418.34

Everest Medicines Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 122.74 272.91 177.38 418.34 326.45
HKSE:01952
42GF Score
Everest Medicines Ltd HKSE:01952
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Everest Medicines Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of HK$326 Mil mean?
Everest Medicines (HKSE:01952) has a Other Current Payables of HK$326 Mil as of Jun. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Everest Medicines and its competitors.
Is Everest Medicines' Other Current Payables too high?
Everest Medicines' current Other Current Payables is HK$326 Mil. Overall, Everest Medicines has a GF Score™ of 42/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Everest Medicines' Other Current Payables compare to VRTX and REGN?
Everest Medicines' Other Current Payables of HK$326 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Everest Medicines and its competitors. Everest Medicines's current Other Current Payables is HK$326 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Everest Medicines stock overvalued right now?
Based on GuruFocus' analysis, Everest Medicines (HKSE:01952) is currently considered Significantly Undervalued. The stock's GF Value™ is HK$210.70, compared to a current price of HK$31.10 — trading 85.2% below its estimated fair value. The current Other Current Payables is HK$326 Mil. Everest Medicines' overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Everest Medicines (HKSE:01952), the current Other Current Payables is HK$326 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Everest Medicines (HKSE:01952) Overvalued in 2026?

Based on GuruFocus' analysis, Everest Medicines stock appears to be undervalued. The current stock price of HK$31.10 is trading 85.2% below its estimated GF Value™ of HK$210.70. GuruFocus considers Everest Medicines to be Significantly Undervalued.

Key valuation signals for HKSE:01952:

  • Other Current Payables: HK$326 Mil
  • GF Value™: HK$210.70 vs. price of HK$31.10 (85.2% below fair value)
  • GF Score™: 42/100 with 4 warning signs

No single metric tells the full story. See the HKSE:01952 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Everest Medicines Business Description

Other Exchanges 6HN:Germany
Address AIA Financial Center, 866 East Changzhi Road, 17th Floor, Hongkou District, Shanghai, CHN, 200082
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes: Nefecon (TarpeyoTM), EVER001, Eravacycline (Xerava), SPR206, and others. Geographically operates in Mainland China.
42GF Score

Get the complete analysis for HKSE:01952

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$31.10
Price
HK$210.70
GF Value